Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TransMedics (TMDX) Gains from Investment Securities (2018 - 2025)

TransMedics (TMDX) has 8 years of Gains from Investment Securities data on record, last reported at $13000.0 in Q4 2025.

  • For Q4 2025, Gains from Investment Securities fell 99.98% year-over-year to $13000.0; the TTM value through Dec 2025 reached $80.1 million, changed 0.01%, while the annual FY2025 figure was $23000.0, 99.97% down from the prior year.
  • Gains from Investment Securities reached $13000.0 in Q4 2025 per TMDX's latest filing, up from $6000.0 in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $80.0 million in Q4 2024 and bottomed at $6000.0 in Q3 2025.
  • Average Gains from Investment Securities over 5 years is $8.3 million, with a median of $687087.5 recorded in 2021.
  • The widest YoY moves for Gains from Investment Securities: up 770.78% in 2025, down 99.98% in 2025.
  • A 5-year view of Gains from Investment Securities shows it stood at $2.8 million in 2021, then soared by 432.36% to $14.9 million in 2022, then surged by 93.57% to $28.8 million in 2023, then surged by 177.5% to $80.0 million in 2024, then crashed by 99.98% to $13000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Gains from Investment Securities were $13000.0 in Q4 2025, $6000.0 in Q3 2025, and $208988.0 in Q1 2025.